QQQ   290.66 (-1.89%)
AAPL   143.26 (-1.83%)
MSFT   243.02 (-2.07%)
META   147.71 (-2.66%)
GOOGL   97.14 (-2.24%)
AMZN   100.78 (-1.43%)
TSLA   168.10 (-5.51%)
NVDA   192.77 (-5.34%)
NIO   12.03 (-5.35%)
BABA   111.46 (-5.85%)
AMD   72.73 (-3.54%)
T   20.18 (+1.15%)
MU   62.01 (-2.91%)
F   12.93 (-2.56%)
CGC   2.85 (-2.73%)
GE   81.09 (-2.57%)
DIS   107.98 (-1.42%)
AMC   5.07 (-7.99%)
PFE   43.58 (-0.48%)
PYPL   80.22 (-1.97%)
NFLX   354.06 (-1.86%)
QQQ   290.66 (-1.89%)
AAPL   143.26 (-1.83%)
MSFT   243.02 (-2.07%)
META   147.71 (-2.66%)
GOOGL   97.14 (-2.24%)
AMZN   100.78 (-1.43%)
TSLA   168.10 (-5.51%)
NVDA   192.77 (-5.34%)
NIO   12.03 (-5.35%)
BABA   111.46 (-5.85%)
AMD   72.73 (-3.54%)
T   20.18 (+1.15%)
MU   62.01 (-2.91%)
F   12.93 (-2.56%)
CGC   2.85 (-2.73%)
GE   81.09 (-2.57%)
DIS   107.98 (-1.42%)
AMC   5.07 (-7.99%)
PFE   43.58 (-0.48%)
PYPL   80.22 (-1.97%)
NFLX   354.06 (-1.86%)
QQQ   290.66 (-1.89%)
AAPL   143.26 (-1.83%)
MSFT   243.02 (-2.07%)
META   147.71 (-2.66%)
GOOGL   97.14 (-2.24%)
AMZN   100.78 (-1.43%)
TSLA   168.10 (-5.51%)
NVDA   192.77 (-5.34%)
NIO   12.03 (-5.35%)
BABA   111.46 (-5.85%)
AMD   72.73 (-3.54%)
T   20.18 (+1.15%)
MU   62.01 (-2.91%)
F   12.93 (-2.56%)
CGC   2.85 (-2.73%)
GE   81.09 (-2.57%)
DIS   107.98 (-1.42%)
AMC   5.07 (-7.99%)
PFE   43.58 (-0.48%)
PYPL   80.22 (-1.97%)
NFLX   354.06 (-1.86%)
QQQ   290.66 (-1.89%)
AAPL   143.26 (-1.83%)
MSFT   243.02 (-2.07%)
META   147.71 (-2.66%)
GOOGL   97.14 (-2.24%)
AMZN   100.78 (-1.43%)
TSLA   168.10 (-5.51%)
NVDA   192.77 (-5.34%)
NIO   12.03 (-5.35%)
BABA   111.46 (-5.85%)
AMD   72.73 (-3.54%)
T   20.18 (+1.15%)
MU   62.01 (-2.91%)
F   12.93 (-2.56%)
CGC   2.85 (-2.73%)
GE   81.09 (-2.57%)
DIS   107.98 (-1.42%)
AMC   5.07 (-7.99%)
PFE   43.58 (-0.48%)
PYPL   80.22 (-1.97%)
NFLX   354.06 (-1.86%)
NASDAQ:SPPI

Spectrum Pharmaceuticals - SPPI Stock Forecast, Price & News

$0.54
-0.03 (-5.11%)
(As of 01/30/2023 04:04 PM ET)
Add
Compare
Today's Range
$0.54
$0.58
50-Day Range
$0.32
$0.60
52-Week Range
$0.32
$1.57
Volume
1.04 million shs
Average Volume
1.35 million shs
Market Capitalization
$101.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Spectrum Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
454.5% Upside
$3.00 Price Target
Short Interest
Healthy
2.73% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
0.79mentions of Spectrum Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$22,500 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.48) to ($0.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

195th out of 1,049 stocks

Pharmaceutical Preparations Industry

93rd out of 514 stocks


SPPI stock logo

About Spectrum Pharmaceuticals (NASDAQ:SPPI) Stock

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.

Receive SPPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SPPI Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Spectrum Shareholder Notice
Solar Industry at Start of Long Bull Run?
The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.
Spectrum Pharmaceuticals Announces Management Changes
See More Headlines
Receive SPPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SPPI Company Calendar

Last Earnings
11/10/2022
Today
1/30/2023
Next Earnings (Estimated)
3/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SPPI
CUSIP
84763A10
Employees
163
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+455.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-158,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.29 per share

Miscellaneous

Free Float
183,084,000
Market Cap
$101.63 million
Optionable
Optionable
Beta
2.03

Social Links


Key Executives

  • Mr. Thomas J. RigaMr. Thomas J. Riga (Age 48)
    Pres, CEO & Director
    Comp: $1.02M
  • Ms. Nora E. Brennan (Age 54)
    Exec. VP & Chief Financial Officer
    Comp: $54.17k
  • Mr. Keith M. McGahan J.D.Mr. Keith M. McGahan J.D. (Age 47)
    L.L.M., Exec. VP, Chief Legal Officer & Corp. Sec.
    Comp: $851.73k
  • Dr. Francois J. Lebel FRCPC (Age 71)
    M.D., Exec. VP & Chief Medical Officer
    Comp: $917.96k
  • Mr. Bimal R. Shah
    VP of Corp. & Bus. Devel.
  • Mr. Michael A. Grabow
    Exec. VP & Chief Bus. Officer
  • Dr. Lyndah K. Dreiling M.B.A.
    M.D., Sr. VP of Clinical Devel.













SPPI Stock - Frequently Asked Questions

Should I buy or sell Spectrum Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SPPI shares.
View SPPI analyst ratings
or view top-rated stocks.

What is Spectrum Pharmaceuticals' stock price forecast for 2023?

4 brokerages have issued 12-month price objectives for Spectrum Pharmaceuticals' stock. Their SPPI share price forecasts range from $1.00 to $4.00. On average, they predict the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 426.3% from the stock's current price.
View analysts price targets for SPPI
or view top-rated stocks among Wall Street analysts.

How have SPPI shares performed in 2023?

Spectrum Pharmaceuticals' stock was trading at $0.3685 on January 1st, 2023. Since then, SPPI stock has increased by 54.7% and is now trading at $0.57.
View the best growth stocks for 2023 here
.

When is Spectrum Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our SPPI earnings forecast
.

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) issued its quarterly earnings results on Thursday, November, 10th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.03.

What is Joseph Turgeon's approval rating as Spectrum Pharmaceuticals' CEO?

2 employees have rated Spectrum Pharmaceuticals Chief Executive Officer Joseph Turgeon on Glassdoor.com. Joseph Turgeon has an approval rating of 47% among the company's employees. This puts Joseph Turgeon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Spectrum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), OPKO Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE).

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $0.57.

How much money does Spectrum Pharmaceuticals make?

Spectrum Pharmaceuticals (NASDAQ:SPPI) has a market capitalization of $107.25 million. The biotechnology company earns $-158,630,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis.

How many employees does Spectrum Pharmaceuticals have?

The company employs 163 workers across the globe.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The official website for the company is www.sppirx.com. The biotechnology company can be reached via phone at (702) 835-6300, via email at ir@sppirx.com, or via fax at 702-260-7405.

This page (NASDAQ:SPPI) was last updated on 1/30/2023 by MarketBeat.com Staff